Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer

American Journal of Clinical Pathology

Volumn 134, Issue 6, 2010, Pages 964-969

  Khoury, Joseph D ^a   Adcock, Dorothy M ^b   Chan, Fanny ^a   Symanowski, James T ^a   Tiefenbacher, Stefan ^b   Goodman, Oscar ^a   Paz, Lazara ^a   Ma, Yupo ^c   Ward, David C ^d   Vogelzang, Nicholas J ^e   Fink, Louis M ^a  

^a NEVADA CANCER INSTITUTE   (United States)

^b Esoterix Inc   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^e Department of Hematology Oncology   (United States)

Author keywords

Circulating tumor cells; D dimer; Prostate cancer; Prostate specific antigen

Indexed keywords

BIOLOGICAL MARKER; D DIMER; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER HORMONE THERAPY; CANCER PATIENT; CASTRATION; CELL COUNT; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

ADENOCARCINOMA; AGED; DISEASE PROGRESSION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 78649636969     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPH92SXYLIKKTS     Document Type: Article

References (40)

1. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
2. Armstrong AJ, Garrett-Mayer E, de Wit R, et al. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16:203-211.
3. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009;27:2450-2456.
4. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
5. Figg WD, Ammerman K, Patronas N, et al. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer. Cancer Invest. 1996;14:513-517. (Pubitemid 26423513)
6. Okotie OT, Aronson WJ, Wieder JA, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171:2260-2264.
7. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213-3221.
8. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781-791.
9. Moreno JG, O'Hara SM, Gross S, et al. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 2001;58:386-392.
10. Danila DC, Heller G, Gignac GA, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:7053-7058. (Pubitemid 350276887)
11. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302-6309.
12. Moreno JG, Miller MC, Gross S, et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65:713-718.
13. Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13:2023-2029.
14. Goodman OB Jr, Fink LM, Symanowski JT, et al. Circulating tumor cells in patients with castrationresistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev. 2009;18:1904-1913.
15. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27:4124-4129.
16. Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer. 2006;53:205-210.
17. Blackwell K, Hurwitz H, Lieberman G, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77-82.
18. Kilic M, Yoldas O, Keskek M, et al. Prognostic value of plasma D-dimer levels in patients with colorectal cancer. Colorectal Dis. 2008;10:238-241. (Pubitemid 351284674)
19. Adcock DM, Fink LM, Marlar RA, et al. The hemostatic system and malignancy. Clin Lymphoma Myeloma. 2008;8:230-236.
20. Kohli M, Fink LM, Spencer HJ, et al. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis. 2002;13:1-5.
21. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302-3309.
22. Lippi G, Franchini M, Targher G, et al. Help me, doctor! My D-dimer is raised. Ann Med. 2008;40:594-605.
23. Geenen RW, Delaere KP, van Wersch JW. Coagulation and fibrinolysis activation markers in prostatic carcinoma patients. Eur J Clin Chem Clin Biochem. 1997;35:69-72.
24. Falanga A. Thrombophilia in cancer. Semin Thromb Hemost. 2005;31:104-110.
25. Costantini V, Zacharski LR. The role of fibrin in tumor metastasis. Cancer Metastasis Rev. 1992;11:283-290.
26. Adamson AS, Francis JL, Witherow RO, et al. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance. Ann R Coll Surg Engl. 1993;75:100-104.
27. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600-608.
28. Stenman UH, Abrahamsson PA, Aus G, et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl. 2005:64-81.
29. Emmenegger U, Ko YJ. PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations. Can Urol Assoc J. 2009;3:375-376.
30. Benchikh El Fegoun A, Villers A, Moreau JL, et al. PSA and follow-up after treatment of prostate cancer [in French]. Prog Urol. 2008;18:137-144.
31. Armstrong AJ, Febbo PG. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. Oncologist. 2009;14:816-827.
32. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233-239.
33. Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial [published online ahead of print April 20, 2010]. Clin Cancer Res. 2010;16:2634-2645.
34. Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009;101:61-66.
35. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004;86:207-213.
36. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359:938-949.
37. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15:6830-6840.
38. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
39. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma [published online ahead of print March 6, 2010]. Exp Cell Res. 2010;316:1324-1331.
40. Taylor RA, Risbridger GP. Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets. 2008;8:490-497.